Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper
Authors:
- Ullrich BetheUBUllrich Bethe
- Zoi D. PanaZPZoi D. Pana
- Christian DrostenCDChristian Drosten
- Herman GoossensHGHerman Goossens
- Franz KönigFKFranz König
- Arnaud MarchantAMArnaud Marchant
- Geert MolenberghsGMGeert Molenberghs
- Martin PoschMPMartin Posch
- Pierre Van DammePDPierre Van Damme
- Oliver A. CornelyOCOliver A. Cornely
Open Access
- 17 July 2024
- journal article
- review article
- Published by Springer Nature in Infection
- Vol. 52 (6) , 2135-2144
Abstract
Background: WHO postulates the application of adaptive design features in the global clinical trial ecosystem. However, the adaptive platform trial (APT) methodology has not been widely adopted in clinical research on vaccines. Methods: The VACCELERATE Consortium organized a two-day workshop to discuss the applicability of APT methodology in vaccine trials under non-pandemic as well as pandemic conditions. Core aspects of the discussions are summarized in this article. Results: An “ever-warm” APT appears ideally suited to improve efficiency and speed of vaccine research. Continuous learning based on accumulating APT trial data allows for pre-planned adaptations during its course. Given the relative design complexity, alignment of all stakeholders at all stages of an APT is central. Vaccine trial modelling is crucial, both before and in a pandemic emergency. Various inferential paradigms are possible (frequentist, likelihood, or Bayesian). The focus in the interpandemic interval may be on research gaps left by industry trials. For activation in emergency, template Disease X protocols of syndromal design for pathogens yet unknown need to be stockpiled and updated regularly. Governance of a vaccine APT should be fully integrated into supranational pandemic response mechanisms. Discussion: A broad range of adaptive features can be applied in platform trials on vaccines. Faster knowledge generation comes with increased complexity of trial design. Design complexity should not preclude simple execution at trial sites. Continuously generated evidence represents a return on investment that will garner societal support for sustainable funding. Adaptive design features will naturally find their way into platform trials on vaccines.Keywords
Funding Information
- Universitätsklinikum Köln
This publication has 31 references indexed in Scilit:
- VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolmentVaccine, 2022
- At the End of Every Pandemic: Beginning a Pandemic Playbook to Respond to the NextFrontiers in Public Health, 2022
- Estimands and Complex Innovative DesignsClinical Pharmacology & Therapeutics, 2022
- The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendationsThe Lancet Infectious Diseases, 2021
- Collaborative Platform Trials to Fight COVID‐19: Methodological and Regulatory Considerations for a Better Societal OutcomeClinical Pharmacology & Therapeutics, 2021
- Innovative trial designs and analyses for vaccine clinical developmentContemporary Clinical Trials, 2021
- Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19Statistics in Biopharmaceutical Research, 2020
- The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designBMJ, 2020
- Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform TrialsClinical Pharmacology & Therapeutics, 2020
- Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)BMC Infectious Diseases, 2017